Das D
Glob Health Med. 2025; 6(6):357-362.
PMID: 39741988
PMC: 11680448.
DOI: 10.35772/ghm.2024.01073.
Ur Rehman M, Chuntakaruk H, Amphan S, Suroengrit A, Hengphasatporn K, Shigeta Y
ACS Bio Med Chem Au. 2024; 4(5):242-256.
PMID: 39431267
PMC: 11487539.
DOI: 10.1021/acsbiomedchemau.4c00040.
Kamaruddin N, Hajri N, Andriani Y, Abdul Manan A, Tengku Muhammad T, Mohamad H
Molecules. 2021; 26(16).
PMID: 34443682
PMC: 8398678.
DOI: 10.3390/molecules26165094.
Zhou Y, Liu P, Dai S, Sun J, Liu Y, Liao X
Antimicrob Agents Chemother. 2020; 65(1).
PMID: 33020156
PMC: 7927862.
DOI: 10.1128/AAC.01172-20.
Shin Y, Park C, Kim H, Kim D, Choi M, Kim J
Virol Sin. 2020; 36(2):254-263.
PMID: 32779073
PMC: 8087725.
DOI: 10.1007/s12250-020-00274-7.
Novel HIV-1 Protease Inhibitors with Morpholine as the P2 Ligand to Enhance Activity against DRV-Resistant Variants.
Zhu M, Dou Y, Ma L, Dong B, Zhang F, Zhang G
ACS Med Chem Lett. 2020; 11(6):1196-1204.
PMID: 32551001
PMC: 7294734.
DOI: 10.1021/acsmedchemlett.0c00043.
Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication.
Maeda K, Das D, Kobayakawa T, Tamamura H, Takeuchi H
Curr Top Med Chem. 2019; 19(18):1621-1649.
PMID: 31424371
PMC: 7132033.
DOI: 10.2174/1568026619666190712204603.
How to Control HTLV-1-Associated Diseases: Preventing Cellular Infection Using Antiviral Therapy.
Pasquier A, Alais S, Roux L, Thoulouze M, Alvarez K, Journo C
Front Microbiol. 2018; 9:278.
PMID: 29593659
PMC: 5859376.
DOI: 10.3389/fmicb.2018.00278.
Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies.
Ghosh A, Martyr C, Osswald H, Sheri V, Kassekert L, Chen S
J Med Chem. 2015; 58(17):6994-7006.
PMID: 26306007
PMC: 4765732.
DOI: 10.1021/acs.jmedchem.5b00900.
4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus.
Takamatsu Y, Tanaka Y, Kohgo S, Murakami S, Singh K, Das D
Hepatology. 2015; 62(4):1024-36.
PMID: 26122273
PMC: 4589464.
DOI: 10.1002/hep.27962.
Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial.
Vanpouille C, Lisco A, Grivel J, Bassit L, Kauffman R, Sanchez J
Clin Infect Dis. 2015; 60(11):1708-14.
PMID: 25740794
PMC: 4447783.
DOI: 10.1093/cid/civ172.
Synthesis, evaluation of anti-HIV-1 and anti-HCV activity of novel 2',3'-dideoxy-2',2'-difluoro-4'-azanucleosides.
Martinez-Montero S, Fernandez S, Sanghvi Y, Theodorakis E, Detorio M, McBrayer T
Bioorg Med Chem. 2012; 20(23):6885-93.
PMID: 23085031
PMC: 3489957.
DOI: 10.1016/j.bmc.2012.09.026.
Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.
Ghosh A, Anderson D, Weber I, Mitsuya H
Angew Chem Int Ed Engl. 2012; 51(8):1778-802.
PMID: 22290878
PMC: 7159617.
DOI: 10.1002/anie.201102762.
Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.
Drake A, Roxby A, Ongecha-Owuor F, Kiarie J, John-Stewart G, Wald A
J Infect Dis. 2011; 205(3):366-75.
PMID: 22147786
PMC: 3256951.
DOI: 10.1093/infdis/jir766.
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic.
Broder S
Antiviral Res. 2009; 85(1):1-18.
PMID: 20018391
PMC: 2815149.
DOI: 10.1016/j.antiviral.2009.10.002.
Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model.
Hiraoka K, Kimura T, Logg C, Tai C, Haga K, Lawson G
Cancer Res. 2007; 67(11):5345-53.
PMID: 17545615
PMC: 8207455.
DOI: 10.1158/0008-5472.CAN-06-4673.
Towards discovering dual functional inhibitors against both wild type and K103N mutant HIV-1 reverse transcriptases: molecular docking and QSAR studies on 4,1-benzoxazepinone analogues.
Zhang Z, Zheng M, Du L, Shen J, Luo X, Zhu W
J Comput Aided Mol Des. 2006; 20(5):281-93.
PMID: 16897578
DOI: 10.1007/s10822-006-9050-6.
Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma.
Tai C, Wang W, Chen T, Kasahara N
Mol Ther. 2005; 12(5):842-51.
PMID: 16257382
PMC: 8185609.
DOI: 10.1016/j.ymthe.2005.03.017.
Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.
Nakata H, Maeda K, Miyakawa T, Shibayama S, Matsuo M, Takaoka Y
J Virol. 2005; 79(4):2087-96.
PMID: 15681411
PMC: 546550.
DOI: 10.1128/JVI.79.4.2087-2096.2005.
4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro.
Kodama E, Kohgo S, Kitano K, Machida H, Gatanaga H, Shigeta S
Antimicrob Agents Chemother. 2001; 45(5):1539-46.
PMID: 11302824
PMC: 90502.
DOI: 10.1128/AAC.45.5.1539-1546.2001.
